Stock Analiz

Amphastar Pharmaceuticals, Inc. (AMPH) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Amphastar Pharmaceuticals’s revenue went from $255M in fiscal 2016 to $720M in fiscal 2025, growth of about 12.2% a year.

Net income in fiscal 2025 was $98M, a net margin of 13.6%; the best year in this period was 2024 with $160M.

Over the twelve months to September 30, 2026, revenue was $746M and net income $99M.

Free cash flow was $121M in fiscal 2025 and positive in 9 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $255M162017: $240M172018: $295M182019: $322M192020: $350M202021: $438M212022: $499M222023: $644M232024: $732M242025: $720M25$720M
Net income
2016: $10M162017: $4M172018: -$6M182019: $49M192020: $1M202021: $62M212022: $91M222023: $138M232024: $160M242025: $98M25$98M
Free cash flow
2016: $17M162017: $4M172018: -$9M182019: $207000192020: $23M202021: $71M212022: $65M222023: $145M232024: $172M242025: $121M25$121M
EPS (diluted)
2016: $0.21162017: $0.08172018: $-0.12182019: $0.98192020: $0.03202021: $1.25212022: $1.74222023: $2.60232024: $3.06242025: $2.0325$2.03

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$746M$720M$732M$644M$499M$438M$350M$322M$295M$240M$255M
Gross profit$349M$356M$374M$351M$249M$200M$143M$132M$107M$91M$104M
Operating income$140M$140M$205M$197M$107M$70M$11M-$39000-$9M-$1M$15M
Net income$99M$98M$160M$138M$91M$62M$1M$49M-$6M$4M$10M
EPS (diluted)$2.19$2.03$3.06$2.60$1.74$1.25$0.03$0.98$-0.12$0.08$0.21
R&D$92M$86M$74M$74M$75M$61M$67M$69M$58M$44M$42M
Revenue growth—−1.7%+13.6%+29.1%+14.0%+25.1%+8.5%+9.4%+22.7%−5.9%+1.5%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$175M$156M$213M$184M$89M$98M$57M$42M$38M$39M$39M
Capital spending-$36M-$35M-$41M-$38M-$24M-$27M-$34M-$42M-$47M-$35M-$21M
Free cash flow$139M$121M$172M$145M$65M$71M$23M$207000-$9M$4M$17M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$96M$76M$85M$58M$40M$29M$24M$22M$25M$31M$10M
Stock-based pay$30M$27M$24M$20M$18M$19M$20M$17M$17M$17M$15M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$283M$222M$257M$176M$137M$106M$85M$89M$68M$73M
Debt—$667M$662M$637M$106M$108M$79M$74M$67M$52M$41M
Equity—$789M$732M$639M$529M$446M$402M$381M$332M$334M$329M
Total assets—$1.6B$1.6B$1.5B$742M$672M$631M$587M$514M$451M$428M
Shares (diluted)43M48M52M53M52M50M49M50M46M48M48M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin46.8%49.5%51.1%54.5%49.9%45.6%41.0%40.9%36.3%37.7%40.8%
Operating margin18.7%19.5%28.1%30.6%21.5%16.0%3.1%-0.0%-2.9%-0.5%6.0%
Net margin13.3%13.6%21.8%21.3%18.3%14.2%0.4%15.2%-1.9%1.5%3.9%
FCF margin18.6%16.8%23.5%22.6%13.1%16.1%6.7%0.1%-2.9%1.7%6.7%
ROIC—7.6%12.4%12.6%13.5%9.5%1.8%-0.0%-1.5%-0.3%2.8%
ROE—12.4%21.8%21.5%17.3%13.9%0.4%12.8%-1.7%1.1%3.0%

Frequently asked questions

What is Amphastar Pharmaceuticals’s annual revenue?

$720M in fiscal 2025 and $746M over the twelve months to September 30, 2026.

How much profit does Amphastar Pharmaceuticals make?

Net income was $98M in fiscal 2025 (net margin 13.6%).

Is Amphastar Pharmaceuticals’s revenue growing?

No: revenue fell 1.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.